(S (NP (NP (JJ Adverse) (NN drug) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NNP ADR)) (-RRB- -RRB-))) (VP (VBZ is) (VP (ADVP (RB widely)) (VBN concerned) (PP (IN for) (NP (JJ public) (NN health) (NN issue))))) (. .))
(S (NP (NNS ADRs)) (VP (VBP are) (NP (NP (CD one)) (PP (IN of) (NP (NP (ADJP (JJS most) (JJ common)) (NNS causes)) (SBAR (S (VP (TO to) (VP (VB withdraw) (NP (DT some) (NNS drugs)) (PP (IN from) (NP (NN market))))))))))) (. .))
(S (NP (NP (NNP Prescription) (NN event) (NN monitoring)) (PRN (-LRB- -LRB-) (NP (NNP PEM)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT an) (JJ important) (NN approach)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (DT the) (JJ adverse) (NN drug) (NNS reactions)))))))) (. .))
(S (NP (NP (DT The) (JJ main) (NN problem)) (SBAR (S (VP (TO to) (VP (VB deal) (PP (IN with) (NP (DT this) (NN method)))))))) (VP (VBZ is) (SBAR (WHADVP (WRB how)) (S (VP (TO to) (VP (ADVP (RB automatically)) (VB extract) (NP (DT the) (NX (NX (JJ medical) (NNS events)) (CC or) (NX (JJ side) (NNS effects)))) (PP (IN from) (NP (NP (JJ high-throughput) (JJ medical) (NNS data)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN collected) (PP (IN from) (NP (ADJP (NN day) (TO to) (NN day)) (JJ clinical) (NN practice)))))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT an) (JJ original) (NN approach)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (DT the) (NNP ADRs)) (S (VP (VBG using) (NP (NP (NN feature) (NN matrix)) (CC and) (NP (NN feature) (NN selection))))))))))) (. .))
(S (NP (DT The) (NNS experiments)) (VP (VBP are) (VP (VBN carried) (PRT (IN out)) (PP (IN on) (NP (NP (DT the) (NN drug)) (NP (NNP Pravastatin)))))) (. .))
(S (NP (NP (JJ Major) (NN side) (NNS effects)) (PP (IN for) (NP (DT the) (NN drug)))) (VP (VBP are) (VP (VBN detected))) (. .))
(S (S (NP (DT The) (JJ detected) (NNP ADRs)) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (JJ computerized) (NN method)))))) (, ,) (S (NP (JJ further) (NN investigation)) (VP (VBZ is) (VP (VBN needed)))) (. .))
